Ginkgo Bioworks Holdings, Inc.
NYSE:DNABiotechnology
+$0.26 today
- Market cap
- $547.12M
- Beta
- 1.80
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.11
Volume 2.36M
Average 1.24M
DNA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Ginkgo Bioworks Holdings, Inc.NYSE: DNA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $12.8M fell 16.7% year over year, behind the +36.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 72.5% from the prior quarter. Over 3 fiscal years it compounded at -1.5% a year.
Context
- Depreciation & amortization amounted to 34.7% of revenue in FY2025, up 6.9 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -16.7% toward the trailing-twelve-month pace of +36.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 58.99M USD
- Year-over-year change
- -6.4%
- 4-year CAGR
- +19.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 58.99M | -6.4% |
| FY2024 | 2024-12-31 | 63.02M | -11.9% |
| FY2023 | 2023-12-31 | 71.55M | +16.1% |
| FY2022 | 2022-12-31 | 61.63M | +112.0% |
| FY2021 | 2021-12-31 | 29.08M | — |
Depreciation & Amortization vs competitors
How DNA compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +36.3% is the 2nd highest of 9, against a peer median of -8.7%.
- Depreciation & amortization amounts to 63.2% of revenue for DNA, versus a peer median of 13.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $89.29M USD | +36.3% | -1.5% | 63.2% | |
| LTM Jun 2026 | $56.96M USD | -3.2% | +16.6% | 27.3% | |
| LTM Sep 2026 | $42.96M USD | -7.4% | +30.8% | 11.3% | |
| LTM Mar 2026 | $12.82M USD | +2.6% | +13.6% | 16.1% | |
| LTM Mar 2026 | $11.62M USD | -10.0% | +19.9% | 17.7% | |
| LTM Mar 2026 | €6.46M EUR | -64.9% | +1.1% | 4.1% | |
| LTM Mar 2026 | $4.5M USD | -21.1% | -14.1% | 5.0% | |
| LTM Dec 2025 | $3.61M USD | -34.2% | +9.0% | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $343K USD | +39.4% | +64.2% | — |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding DNA) | — | -8.7% | +15.1% | 13.7% | |
Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 313.84M | 477.71M | 251.46M | 227.04M | 170.16M |
| Cost of Revenue | 129.69M | 204.22M | 54.01M | 38.55M | 31.52M |
| Gross Profit | 184.15M | 273.49M | 197.45M | 188.49M | 138.63M |
| Gross Margin | 58.7% | 57.3% | 78.5% | 83.0% | 81.5% |
| Research & Development | 1.15B | 1.05B | 580.62M | 424.06M | 243.77M |
| Selling, General & Admin | 862.95M | 1.43B | 385.03M | 246.16M | 183.29M |
| Operating Expenses | 2.01B | 2.48B | 1.06B | 748.25M | 453.91M |
| Depreciation & Amortization | 29.08M | 61.63M | 71.55M | 63.02M | 58.99M |
| EBITDA | (1.81B) | (2.06B) | (821.29M) | (484.39M) | (254.61M) |
| EBITDA Margin | -575.7% | -431.2% | -326.6% | -213.3% | -149.6% |
| Operating Income | (1.83B) | (2.21B) | (864.41M) | (559.76M) | (315.28M) |
| Operating Margin | -582.6% | -462.4% | -343.8% | -246.5% | -185.3% |
| Interest Income | 837K | 20.26M | 57.22M | 38.61M | 22.62M |
| Interest Expense | 2.37M | 106K | 93K | 94K | 0 |
| Other Income / Expenses | (9.66M) | 87.55M | (28.53M) | 12.25M | 1.68M |
| Income Before Tax | (1.84B) | (2.12B) | (892.94M) | (547.51M) | (313.6M) |
| Pre-Tax Margin | -585.7% | -444.1% | -355.1% | -241.1% | -184.3% |
| Income Tax Expense | (1.48M) | (15.03M) | (71K) | (479K) | (837K) |
| Net Income | (1.83B) | (2.1B) | (892.87M) | (547.03M) | (312.76M) |
| Net Margin | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% |
| EPS (Basic) | (53.83) | (50.15) | (18.37) | (10.54) | (5.64) |
| EPS (Diluted) | (55.53) | (50.20) | (18.40) | (10.54) | (5.64) |
| Weighted Avg Shares | 32.95M | 41.93M | 48.53M | 51.89M | 55.46M |
| Weighted Avg Shares (Diluted) | 34.01M | 42M | 48.61M | 51.89M | 55.46M |
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
Intrinsic Alpha fair value
Locked
Current Price
$8.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.